• Investors
  • News
  • Careers
  • Contact
  • Global Need
    • Vaccines
    • History & Impact
  • Our Solution
    • Oral Vaccines
    • Technology
    • Vaccine Advantages
    • Platform Advantages
  • Pipeline
    • Research & Development
    • Norovirus
    • Influenza
    • RSV
    • HPV
  • About Us
    • Our Mission
    • Our Team
    • Careers
    • Contact
    • Compliance
  • Investors
  • News
  • Careers
  • Contact

Single

An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling

Dora EG, Rossi SL, Weaver SC, Tucker SN, Mateo R. Vaccine. 2019 May 27;37(24):3146-3150. doi: 10.1016/j.vaccine.2019.04.069. Epub 2019 Apr 29.

Post navigation

Previous PostPrevious
Media Contacts

Katie Hogan, WCG
415.658.9745
khogan@wcgworld.com

Samir Singh, Vaxart
908.720.622,4
ssignh@vaxart.com

Get Updates

Subscribe to receive news alerts now.

© 2021 Vaxart, Inc., All rights reserved. Terms of UsePrivacy Policy